Herstellerprofil
Bausch & Lomb Incorporated
Pharmaunternehmen4 erfasste Produkte
4
erfasste Produkte
73.260
Meldungen insgesamt
23
dokumentierte Rückrufe
47,8%
schwerwiegend insgesamt
Produkte
4 von 4 angezeigt
| Produkt | Zugelassen | Meldungen ↓ | Top-Signal | Rückrufe |
|---|---|---|---|---|
| 2001 | 27.882 | Erhöhter Augeninnendruck | 9 | |
| 2001 | 27.882 | Erhöhter Augeninnendruck | 10 | |
| 2016 | 16.017 | Reaktion an der Applikationsstelle | 4 | |
| — | 1.479 | Polypoidale choroidale Vaskulopathie | 0 |
Rückrufhistorie · 14 dokumentiert
| Datum | Klasse | Grund | Firma |
|---|---|---|---|
| 5. März 2026 | II | Lack of Assurance of Sterility | Apotex Corp. |
| 5. Sept. 2025 | II | Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns | Apotex Corp. |
| 28. Mai 2025 | II | Lack of Assurance of Sterility | Apotex Corp. |
| 1. März 2023 | II | Lack of sterility assurance: Cracks have developed in some of the units caps of Brimonidine tartrate ophthalmic solution bottles. There is a possibility the broken cap may impact sterility. | Apotex Corp. |
| 10. Mai 2022 | III | Failed Impurities/Degradation Specifications. | Novartis Pharmaceuticals Corporation |
| 10. Mai 2022 | III | Failed Impurities/Degradation Specifications. | Novartis Pharmaceuticals Corporation |
| 10. Mai 2022 | III | Failed Impurities/Degradation Specifications. | Novartis Pharmaceuticals Corporation |
| 10. Mai 2022 | III | Failed Impurities/Degradation Specifications. | Novartis Pharmaceuticals Corporation |
| 4. Juni 2020 | III | Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life. | SOMERSET THERAPEUTICS LLC |
| 4. Juni 2020 | III | Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life. | SOMERSET THERAPEUTICS LLC |
| 4. Juni 2020 | III | Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life. | SOMERSET THERAPEUTICS LLC |
| 19. März 2019 | II | cGMP Deviations | Allergan Sales, LLC |
| 19. Okt. 2017 | III | Failed Impurities/Degradation Specifications. | Allergan Sales, LLC |
| 23. Juni 2017 | II | Incorrect/Undeclared Excipient; non-pharmaceutical grade PEG 40 Castor Oil was used due to a mislabeling by the supplier | ImprimisRx CA, Inc., dba ImprimisRx |
Klasse I = begründete Wahrscheinlichkeit schwerwiegender Schäden · Klasse II = vorübergehend oder reversibel · Klasse III = Schaden unwahrscheinlich.
Registrierungsstatus
Einige Produkte von Bausch & Lomb Incorporated sind nicht für die Anwendung am Menschen FDA-registriert. Für nicht registrierte Substanzen (Peptide, SARMs ohne Humanzulassung) existiert kein legitimer Anbieter für die Anwendung am Menschen. Das Fehlen eines Bezugswegs ist die Sicherheitsinformation.